BiotechTV

𝐅𝐫𝐨𝐦 𝐉𝐚𝐩𝐚𝐧: An overview of 中外製薬 / Chugai Pharmaceutical Co., Ltd., including its global ambitions and R&D capabilities, with the company’s CEO, Dr. Osamu Okuda, in Tokyo. Dr. Okuda describes Chugai’s vision to be a Top Innovator in 2030, the science that the company excels in, including unique midsize molecules, program highlights in areas such as oncology, hemophilia, and obesity, Japan’s biotech ecosystem, and more. Full video: https://lnkd.in/gBxuKJec BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐂𝐚𝐦𝐛𝐫𝐢𝐝𝐠𝐞, 𝐔𝐊: Microbiotica is working on microbiome therapies in Cambridge, UK, with lead programs in immuno-oncology and inflammatory bowel disease. CEO Tim Sharpington describes the advances that have been made in the microbiome field over the last decade and introduces us to Microbiotica's programs. Full video: https://lnkd.in/gKkPxQ7e BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Cambridge, UK based Mestag Therapeutics last month announced a license and research collaboration with MSD to leverage the company's fibroblast platform to find inflammatory disease targets. CEO Susan Hill describes the role that fibroblasts play in regulating immune responses to inflammatory conditions and how Mestag is leveraging this in drug development. It now has the partnership with MSD, as well as a prior one with Janssen, and it's own assets in oncology and autoimmune disease. Full video: https://lnkd.in/gjRSF4Vs BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐉𝐚𝐩𝐚𝐧: Tokyo based TMS Co., Ltd. has a lead program that aims to be the first new medicine for acute ischemic stroke in decades. CEO Takuro Wakabayashi describes the unmet need in stroke and how this asset found its way into to a partnership with RTW Investments, LP-based CORXEL Pharmaceuticals. Plus, further pipeline programs covering hypertension, kidney injury, and spinal cord injury. Full video: https://lnkd.in/gtjdhM5k BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐉𝐚𝐩𝐚𝐧: Tokyo based Heartseed Inc. is leveraging its expertise iPSCs and regenerative medicine to solve unmet needs in cardiovascular disease like heart failure. Founder and CEO Keiichi Fukuda describes the qualities that Heartseed has built into the cardiomyocytes it is developing to make them potent and durable for patients with cardiovascular disease. Six patients have already been dosed in a proof-of-concept clinical trial in Japan. Full video: https://lnkd.in/g_g7hmTK BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc. | NYSE | Allucent | Klein Hersh

𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Johnson & Johnson's Elena Diez Cecilia, PhD, MBA, and Odyssey Therapeutics' Gary D. Glick share advice on success factors for pharma - biotech partnerships, and more. They discuss Odyssey's work, the investments it has made regarding in silico and AI/ML tools, the unique value of the Boston biotech ecosystem, and keys to successful collaborations. Full video: https://lnkd.in/gzWvGBGB The Studio at Kendall Square episodes are brought to you by MassBio BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

𝐁𝐫𝐢𝐧𝐠𝐢𝐧𝐠 𝐚 𝐧𝐞𝐰 𝐜𝐥𝐚𝐬𝐬 𝐨𝐟 𝐝𝐫𝐮𝐠𝐬 𝐭𝐨 𝐦𝐚𝐫𝐤𝐞𝐭: 𝐏𝐬𝐲𝐜𝐡𝐞𝐝𝐞𝐥𝐢𝐜𝐬: Allucent's Marcus Delatte, PhD, PhD, Vice President of Regulatory Strategy, talks about best practices for small and mid-sized biotechs bringing a new class of drugs to market safely and effectively for patients suffering from PTSD, depression, and other conditions. #Sponsored

𝐒𝐈𝐓𝐂 𝟐𝟎𝟐𝟒: Aulos Bioscience's CEO Aron Knickerbocker describes the phase 1 and preliminary phase 2 data for the company's IL-2 redirecting antibody. He describes the safety and preliminary efficacy they have seen, including how patirents are experiencing a lowering of Tregs. Plus, the future of the therapy in melanoma, lung cancer, and beyond. #SITC24 Full video: https://lnkd.in/gUrAGPv9 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

𝐒𝐈𝐓𝐂 𝟐𝟎𝟐𝟒: Marengo Therapeutics CEO Zhen Su, MD MBA discusses the first-in-human data for the company's lead program, Invikafusp Alfa. He describes how this dual T-cell agonist is designed to cause the expansion and reprogramming of TIL's in the body. Plus, an update on Marengo's partnerships with Ipsen and Gilead, and his take on key highlights from this year's SITC annual meeting. #SITC24 Full video: https://lnkd.in/gJGcPZHP BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh

𝐒𝐈𝐓𝐂 𝟐𝟎𝟐𝟒: Compugen CEO discusses ovarian cancer data for her company's TIGIT + PVRIG + pembro triplet combo. Anat Cohen-Dayag describes this SITC data, shares her opinion on the TIGIT field, and highlights an IL-18 program that is partnered with Gilead. #SITC24 Full video: https://lnkd.in/gPU-7npT BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent | Klein Hersh